Shree Ganesh Remedies Ltd

Shree Ganesh Remedies, a small-cap pharmaceutical company, has faced notable stock volatility, declining for two consecutive days and experiencing a significant drop today. Despite recent challenges, the stock has shown a positive trend over the past month, outperforming the broader market index, the Sensex.

Shree Ganesh Remedies has announced its financial results for the quarter ending February 2025, showing stable performance in Q3 FY24-25. However, the company's stock evaluation score has notably decreased, indicating a shift in the assessment of its financial standing, prompting potential scrutiny from stakeholders.

Shree Ganesh Remedies, a small-cap pharmaceutical company, faced notable stock volatility on February 5, 2025, with significant intraday fluctuations. Despite a decline today, the stock remains above its key moving averages and has shown a positive return over the past month, contrasting with broader market trends.

Shree Ganesh Remedies, a small-cap pharmaceutical company, faced notable stock volatility on February 5, 2025, with significant intraday fluctuations. Despite a decline today, the stock remains above its key moving averages and has shown a positive return over the past month, contrasting with broader market trends.

Shree Ganesh Remedies, a small-cap pharmaceutical company, experienced notable trading activity on February 4, 2025, rebounding after two days of decline. The stock outperformed its sector and demonstrated high volatility, while also trading above multiple moving averages, indicating a positive trend over the past month.

Shree Ganesh Remedies, a small-cap pharmaceutical company, experienced notable trading activity on February 4, 2025, rebounding after two days of decline. The stock outperformed its sector and demonstrated high volatility, while also trading above multiple moving averages, indicating a positive trend over the past month.

Shree Ganesh Remedies, a small-cap pharmaceutical company, has seen notable stock activity, gaining 17.83% on January 31, 2025. The stock has outperformed its sector significantly and demonstrated strong momentum, with a total return of 28.78% over three days and impressive gains over the past month.

Shree Ganesh Remedies has experienced a revision in its score by MarketsMOJO following a recent assessment of its financial performance. Despite a solid return on equity and healthy long-term growth, the stock's valuation concerns and underperformance relative to the market have led to adjustments in its evaluation. Additionally, it has been added to MarketsMOJO's list, indicating a notable shift in market sentiment.

Shree Ganesh Remedies has recently experienced a revision in its stock evaluation by MarketsMOJO, reflecting a positive shift in its market outlook. The company’s strong long-term growth, low debt levels, and improved technical indicators contribute to this adjustment. However, investors should remain cautious regarding its valuation and market sentiment.

Shree Ganesh Remedies, a microcap pharmaceutical company, has been downgraded to 'Sell' by MarketsMOJO due to its flat results and expensive valuation. Domestic mutual funds hold 0% of the company, indicating potential concerns. However, the company has a low debt to equity ratio and has shown healthy long-term growth. The technical trend is currently sideways, resulting in a -3.45% return since the downgrade. Despite outperforming the market in the past year, caution may be advised for investors.

Shree Ganesh Remedies, a microcap pharmaceutical company, reported a flat performance in the second quarter of fiscal year 2024-2025. However, the company's Profit After Tax (PAT) for the nine-month period has seen a 33.00% year on year growth, reaching Rs 23.66 crore. This indicates a positive trend in the near term for the company's financials.

On October 29th, 2024, Shree Ganesh Remedies, a smallcap pharmaceutical company, saw a rise of 8.07% in its stock, outperforming the sector by 8.75%. This marks the second consecutive day of gains for the company, with a total rise of 8.75%. The stock is currently trading higher than its moving averages and has outperformed the market, showcasing its strong performance and potential for growth in the pharmaceutical sector.

Shree Ganesh Remedies, a microcap pharmaceutical company, has received a 'Hold' rating from MarketsMOJO due to its low Debt to Equity ratio and consistent growth in Net Sales. The stock has outperformed the market and is currently in a Mildly Bullish range. However, its recent quarterly results were flat and the stock is trading at a discount compared to its historical valuations. Domestic mutual funds hold 0% of the company, but with its strong financials and market-beating performance, Shree Ganesh Remedies remains a promising player in the pharmaceutical industry.

Shree Ganesh Remedies, a microcap pharmaceutical company, has been downgraded to a 'Sell' by MarketsMOJO due to its flat results and high ROCE. Domestic mutual funds hold a 0% stake, while the stock's technical trend is sideways. Despite outperforming the market, its profits have only risen by 44.5%, making it a risky investment option.

Shree Ganesh Remedies, a smallcap pharmaceutical company, has received an upgraded stock call from MarketsMOJO to 'Hold'. The decision is based on factors such as low Debt to Equity ratio, healthy long-term growth, and technical indicators showing a Bullish trend. However, the company's recent results were flat and its valuation may be slightly expensive. Domestic mutual funds hold 0% of the company, suggesting caution for potential investors.

Shree Ganesh Remedies, a smallcap pharmaceutical company, has been downgraded to 'Sell' by MarketsMOJO due to its flat results in the June 2024 quarter and high ROCE. Despite healthy long-term growth, domestic mutual funds hold 0% of the company, and technical trends show no clear price momentum. Caution is advised for potential investors.

On September 4th, 2024, Shree Ganesh Remedies, a smallcap pharmaceutical company, saw a 7.45% increase in its stock, outperforming the sector by 6.8%. This marks the second consecutive day of gains, with a total increase of 13.93% in the past two days. The stock is currently trading above its moving averages and is rated as 'Hold' by MarketsMOJO. It has also outperformed the overall market in the past day and month, indicating a positive trend for the company.